576 related articles for article (PubMed ID: 33950462)
1. MRD Assessment in Multiple Myeloma: Progress and Challenges.
Bertamini L; D'Agostino M; Gay F
Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
[TBL] [Abstract][Full Text] [Related]
2. Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.
Diamond BT; Rustad E; Maclachlan K; Thoren K; Ho C; Roshal M; Ulaner GA; Landgren CO
Blood Rev; 2021 Mar; 46():100732. PubMed ID: 32771227
[TBL] [Abstract][Full Text] [Related]
3. Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma.
Jamet B; Zamagni E; Nanni C; Bailly C; Carlier T; Touzeau C; Michaud AV; Moreau P; Bodet-Milin C; Kraeber-Bodere F
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751375
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
Waldschmidt JM; Anand P; Knoechel B; Lohr JG
Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
[TBL] [Abstract][Full Text] [Related]
5. Measurable Residual Disease and Decision-Making in Multiple Myeloma.
Derman BA; Fonseca R
Hematol Oncol Clin North Am; 2024 Apr; 38(2):477-495. PubMed ID: 38184470
[TBL] [Abstract][Full Text] [Related]
6. Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.
Langerhorst P; Noori S; Zajec M; De Rijke YB; Gloerich J; van Gool AJ; Caillon H; Joosten I; Luider TM; Corre J; VanDuijn MM; Dejoie T; Jacobs JFM
Clin Chem; 2021 Nov; 67(12):1689-1698. PubMed ID: 34643690
[TBL] [Abstract][Full Text] [Related]
7. What to do with minimal residual disease testing in myeloma.
Manasanch EE
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):137-141. PubMed ID: 31808833
[TBL] [Abstract][Full Text] [Related]
8. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma.
Medina A; Puig N; Flores-Montero J; Jimenez C; Sarasquete ME; Garcia-Alvarez M; Prieto-Conde I; Chillon C; Alcoceba M; Gutierrez NC; Oriol A; Rosinol L; Bladè J; Gironella M; Hernandez MT; Gonzalez-Calle V; Cedena MT; Paiva B; San-Miguel JF; Lahuerta JJ; Mateos MV; Martinez-Lopez J; Orfao A; Gonzalez M; Garcia-Sanz R
Blood Cancer J; 2020 Oct; 10(10):108. PubMed ID: 33127891
[TBL] [Abstract][Full Text] [Related]
9. Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.
Fonseca R; Arribas M; Wiedmeier-Nutor JE; Kusne YN; González Vélez M; Kosiorek HE; Butterfield RDJ; Kirsch IR; Mikhael JR; Stewart AK; Reeder C; Larsen J; Bergsagel PL; Fonseca R
Blood Cancer J; 2023 Mar; 13(1):32. PubMed ID: 36878906
[TBL] [Abstract][Full Text] [Related]
10. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
[TBL] [Abstract][Full Text] [Related]
11. Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma.
Yao Q; Bai Y; Orfao A; Kumar S; Chim CS
J Mol Diagn; 2020 May; 22(5):679-684. PubMed ID: 32151713
[TBL] [Abstract][Full Text] [Related]
12. Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma.
Bal S; Costa LJ
Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 1(1):1-20. PubMed ID: 33843859
[TBL] [Abstract][Full Text] [Related]
13. Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma.
Abeykoon JP; Murray DL; Murray I; Jevremovic D; Otteson GE; Dispenzieri A; Arendt BK; Dasari S; Gertz M; Gonsalves WI; Kourelis TV; Muchtar E; Dingli D; Warsame R; Go RS; Lacy MQ; Leung N; Buadi F; Lin Y; Kyle RA; Rajkumar V; Kumar S; Kapoor P
Br J Haematol; 2021 Apr; 193(2):380-385. PubMed ID: 33216966
[TBL] [Abstract][Full Text] [Related]
14. Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.
Martinez-Lopez J; Alonso R; Wong SW; Rios R; Shah N; Ruiz-Heredia Y; Sanchez-Pina JM; Sanchez R; Bahri N; Zamanillo I; Poza M; Buenache N; Encinas C; Juarez L; Miras F; Collado L; Barrio S; Martin T; Cedena MT; Wolf J
J Hematol Oncol; 2021 Aug; 14(1):126. PubMed ID: 34404440
[TBL] [Abstract][Full Text] [Related]
15. New criteria for response assessment: role of minimal residual disease in multiple myeloma.
Paiva B; van Dongen JJ; Orfao A
Blood; 2015 May; 125(20):3059-68. PubMed ID: 25838346
[TBL] [Abstract][Full Text] [Related]
16. Multiple myeloma: disease response assessment.
Zamagni E; Tacchetti P; Terragna C; Cavo M
Expert Rev Hematol; 2016 Sep; 9(9):831-7. PubMed ID: 27409577
[TBL] [Abstract][Full Text] [Related]
17. Minimal Residual Disease in Multiple Myeloma: an Important Tool in Clinical Trials.
Gozzetti A; Bocchia M
Rev Recent Clin Trials; 2022; 17(1):9-10. PubMed ID: 34814822
[TBL] [Abstract][Full Text] [Related]
18. Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.
Anderson KC; Auclair D; Adam SJ; Agarwal A; Anderson M; Avet-Loiseau H; Bustoros M; Chapman J; Connors DE; Dash A; Di Bacco A; Du L; Facon T; Flores-Montero J; Gay F; Ghobrial IM; Gormley NJ; Gupta I; Higley H; Hillengass J; Kanapuru B; Kazandjian D; Kelloff GJ; Kirsch IR; Kremer B; Landgren O; Lightbody E; Lomas OC; Lonial S; Mateos MV; Montes de Oca R; Mukundan L; Munshi NC; O'Donnell EK; Orfao A; Paiva B; Patel R; Pugh TJ; Ramasamy K; Ray J; Roshal M; Ross JA; Sigman CC; Thoren KL; Trudel S; Ulaner G; Valente N; Weiss BM; Zamagni E; Kumar SK
Clin Cancer Res; 2021 Oct; 27(19):5195-5212. PubMed ID: 34321279
[TBL] [Abstract][Full Text] [Related]
19. Molecular detection of minimal residual disease in multiple myeloma.
Bai Y; Orfao A; Chim CS
Br J Haematol; 2018 Apr; 181(1):11-26. PubMed ID: 29265356
[TBL] [Abstract][Full Text] [Related]
20. Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma.
Foureau DM; Paul BA; Guo F; Lipford EH; Fesenkova K; Tjaden E; Drummond K; Bhutani M; Atrash S; Ndiaye A; Varga C; Voorhees PM; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e41-e50. PubMed ID: 36443182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
